Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols

Age-related differences in the distribution, biology and treatment response of non-Hodgkin's lymphoma (NHL) in adolescents remain to be elucidated. The current analyses present clinical parameters and outcomes of adolescents treated in pediatric NHL-BFM trials. Patients were stratified by histo...

Full description

Saved in:
Bibliographic Details
Published inLeukemia Vol. 25; no. 1; pp. 153 - 160
Main Authors Burkhardt, B, Oschlies, I, Klapper, W, Zimmermann, M, Woessmann, W, Meinhardt, A, Landmann, E, Attarbaschi, A, Niggli, F, Schrappe, M, Reiter, A
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.01.2011
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Age-related differences in the distribution, biology and treatment response of non-Hodgkin's lymphoma (NHL) in adolescents remain to be elucidated. The current analyses present clinical parameters and outcomes of adolescents treated in pediatric NHL-BFM trials. Patients were stratified by histological subtype: lymphoblastic lymphoma (LBL); mature B-NHL, including Burkitt's lymphoma/leukemia (BL/B-AL), diffuse B-cell lymphoma (DLBCL-CB) and mediastinal B-cell lymphoma (PMLBL); and anaplastic large cell lymphoma (ALCL). Between October 1986 and December 2007, 2915 patients were registered, including 378 (13%) adolescents (15–18 years) with BL/B-AL ( n =101), ALCL ( n =74), DLBCL-CB ( n =55), T-LBL ( n =45), PMLBL ( n =24), pB-LBL ( n =13) and rare or not-specified NHL subtypes ( n =66). The 5-year event-free survival (EFS) was 79±2% for adolescents compared with 85±1% for patients aged <15 years ( P =0.014). EFS was 83±7% for adolescents with T-LBL, 82±4% with BL/B-AL, 85±5% with DLBCL-CB, 57±10% with PMLBL and 70±6% with ALCL. According to sex, the 5-year EFS in females versus males, respectively, was 70±5 versus 83±2% overall ( P =0.004), 57±17 versus 92±6% ( P =0.0036) for T-LBL patients and 71±9 versus 97±3% ( P =0.0067) for DLBCL-CB patients. Adolescents with NHL treated according to pediatric NHL-BFM protocols had an EFS of 79±2%, which is marginally inferior to that of children. In adolescents with T-LBL and DLBCL-CB, female sex was associated with a worse prognosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2010.245